Verition Fund Management
ACRS icon

Verition Fund Management’s Aclaris Therapeutics ACRS Stock Holding History

Verition Fund Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-35,805
Closed -$54.8K – 3609
2025
Q1 		$54.8K Buy
+35,805
New +$76.4K ﹤0.01% 3193
2024
Q3 		– Sell
-82,883
Closed -$91.2K – 3148
2024
Q2 		$91.2K Buy
82,883
+29,048
+54% +$34.1K ﹤0.01% 2737
2024
Q1 		$66.8K Buy
+53,835
New +$64.2K ﹤0.01% 2620
2023
Q4 		– Sell
-299,685
Closed -$2.05M – 2294
2023
Q3 		$2.05M Sell
299,685
-351,242
-54% -$3M 0.02% 782
2023
Q2 		$6.75M Buy
650,927
+37,475
+6% +$339K 0.09% 296
2023
Q1 		$4.96M Buy
613,452
+207,884
+51% +$2.64M 0.07% 370
2022
Q4 		$6.39M Buy
405,568
+33,061
+9% +$532K 0.1% 249
2022
Q3 		$5.86M Buy
372,507
+37,841
+11% +$596K 0.07% 362
2022
Q2 		$4.67M Buy
334,666
+79,188
+31% +$1.11M 0.09% 285
2022
Q1 		$4.4M Buy
255,478
+77,168
+43% +$1.05M 0.05% 451
2021
Q4 		$2.59M Buy
+178,310
New +$2.7M 0.02% 706
2021
Q1 		– Sell
-98,845
Closed -$640K – 1521
2020
Q4 		$640K Buy
+98,845
New +$417K 0.01% 602
2020
Q3 		– Sell
-65,000
Closed -$105K – 1030
2020
Q2 		$105K Buy
+65,000
New +$87.1K ﹤0.01% 998

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Verition Fund Management's ACRS Position: Q2 2025 in Review

Verition Fund Management sold out of Aclaris Therapeutics (ACRS) in Q2 2025, closing a stake of 35,805 shares — an estimated $54.8K sold.

Verition Fund Management first reported a position in ACRS in Q2 2020 and held it in 13 quarters. The position peaked at $6.75M in Q2 2023. 96 funds tracked by Wall St. Rank hold ACRS as of Q2 2025.

  • Verition Fund Management reported no remaining Aclaris Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Verition Fund Management sold 35,805 Aclaris Therapeutics shares in Q2 2025, an estimated $54.8K.
  • Verition Fund Management first reported a position in Aclaris Therapeutics in Q2 2020 and held it in 13 quarters.
  • Verition Fund Management's Aclaris Therapeutics position peaked at $6.75M in Q2 2023.
  • 96 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2025.

Based on Verition Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.